MECL-1 Inhibitors

The chemical class of MECL-1 inhibitors comprises a range of compounds that predominantly target the proteasome system, thereby indirectly affecting the activity of MECL-1. This class includes several specific proteasome inhibitors, such as bortezomib, carfilzomib, and MLN9708 (Ixazomib), known for their potent inhibitory effects on proteasomal degradation. These inhibitors function by binding to the proteasome and obstructing its proteolytic activity, which can lead to a decrease in MECL-1 activity as part of the broader impact on the proteasome system.

Compounds like ONX 0914 and oprozomib, which are more selective towards the immunoproteasome, represent a targeted approach within this class. Their selective inhibition of the immunoproteasome subunits, including MECL-1, highlights their ability in specifically reducing MECL-1 function. Lactacystin, though initially increasing proteasome subunit levels, can lead to an overall inhibition of proteasome activity upon prolonged exposure, thereby affecting MECL-1 function. Additionally, compounds with off-target effects on proteasomes, such as nelfinavir, an HIV protease inhibitor, are also included in this class. Their broader range of action can inadvertently lead to decreased MECL-1 activity as part of the inhibition of proteasome function. Natural compounds like celastrol and betulinic acid, known for their anti-proteasomal activity, further expand the diversity of this class. They exhibit their inhibitory effects by inducing proteotoxic stress and disrupting normal proteasome function, respectively.